Udit Batra, the company’s President and CEO, brings a knowledge, not only of the lab customer, but the global pharmaceutical consumer, to his new role.
Comparing manufacturing methods for one immediate-release low-dose form, we found that dry blend needed less equipment and was more “QbD-ready” than wet granulation or geometric dilution.
Bridging the gap between formulation and tablet manufacturing, pharmaceutical formulation intermediate (PFI) outsourcing promises sponsors time and cost reduction